Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified November 2013 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified March 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified March 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified March 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified March 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery
Conditions: Stage I Uterine Sarcoma; Uterine LeiomyosarcomaInterventions: Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: docetaxel; Biological: filgrastim; Biological: pegfilgrastim; Other: clinical observationSponsors: Gynecologic Oncology Group; National Cancer Institute (NCI)Recruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 11, 2012 Category: Research Source Type: clinical trials